Related Experiment Video
Updated: Mar 19, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Integrated genetic and pharmacologic interrogation of rare cancers
Andrew L Hong1,2,3, Yuen-Yi Tseng3, Glenn S Cowley3
1Boston Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA.
Abstract:
Identifying therapeutic targets in rare cancers remains challenging due to the paucity of established models to perform preclinical studies. As a proof-of-concept, we developed a patient-derived cancer cell line, CLF-PED-015-T, from a paediatric patient with a rare undifferentiated sarcoma. Here, we confirm that this cell line recapitulates the histology and harbours the majority of the somatic genetic alterations found in a metastatic lesion isolated at first relapse. We then perform pooled CRISPR-Cas9 and RNAi loss-of-function screens and a small-molecule screen focused on druggable cancer targets. Integrating these three complementary and orthogonal methods, we identify CDK4 and XPO1 as potential therapeutic targets in this cancer, which has no known alterations in these genes. These observations establish an approach that integrates new patient-derived models, functional genomics and chemical screens to facilitate the discovery of targets in rare cancers.
Insights
Researchers developed a new patient-derived cell line for studying rare pediatric sarcomas. This model helped identify CDK4 and XPO1 as potential therapeutic targets for this challenging cancer.
Area of Science:
- Oncology
- Genetics
- Drug Discovery
Background:
- Identifying therapeutic targets in rare cancers is difficult due to a lack of preclinical models.
- Patient-derived models are crucial for understanding rare cancer biology and testing therapies.
Purpose of the Study:
- To develop and validate a patient-derived cell line for a rare pediatric undifferentiated sarcoma.
- To identify novel therapeutic targets using functional genomics and chemical screening approaches.
Main Methods:
- Established a patient-derived cancer cell line (CLF-PED-015-T) from a pediatric sarcoma.
- Performed pooled CRISPR-Cas9 and RNAi loss-of-function screens.
- Conducted a small-molecule screen targeting druggable cancer pathways.
Main Results:
- The CLF-PED-015-T cell line accurately reflected the patient's tumor histology and genetic alterations.
- Integrated screening data identified Cyclin-Dependent Kinase 4 (CDK4) and Exportin 1 (XPO1) as potential therapeutic targets.
- These targets were validated despite no known genetic alterations in the original tumor.
Conclusions:
- A novel patient-derived model facilitates rare cancer research.
- An integrated approach combining functional genomics and chemical screening can uncover actionable targets in rare cancers.
- CDK4 and XPO1 represent promising targets for therapeutic intervention in this rare sarcoma.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Pharmacogenomics: Identification of New Drug Targets